Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The primary aim of this dose-finding study is to determine the maximum tolerated dose of
taxotere, eloxatin and capecitabine (TEX) in combination with herceptin given every third
week as first-line treatment in patients with HER2-positive advanced gastro-esophageal
cancer. Secondary end points are to evaluate progression-free survival and overall survival.
Phase:
N/A
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Aarhus University Hospital Rigshospitalet, Denmark